Technical Analysis for ITCI - Intra-Cellular Therapies Inc.

Grade Last Price % Change Price Change
B 36.82 -2.07% -0.78
ITCI closed down 0.69 percent on Friday, May 14, 2021, on approximately normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical ITCI trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish -2.19%
Slingshot Bullish Bullish Swing Setup -2.19%
Upper Bollinger Band Walk Strength -2.19%
Wide Bands Range Expansion -2.19%
Overbought Stochastic Strength -2.19%
Stochastic Sell Signal Bearish -2.87%
Upper Bollinger Band Walk Strength -2.87%
Overbought Stochastic Strength -2.87%
Up 3 Days in a Row Strength -2.87%
Up 4 Days in a Row Strength -2.87%
Older End-of-Day Signals for ITCI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown 43 minutes ago
Down 2 % 43 minutes ago
Fell Below Previous Day's Low 43 minutes ago
Down 1% about 3 hours ago
Up 1% about 3 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Intra-Cellular Therapies Inc. Description

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS). Its lead product candidate includes ITI-007, which is in various clinical trials for the treatment of exacerbated and residual schizophrenia; bipolar disorders; sleep deficits associated with neurologic and psychiatric disorders; behavioral disturbances associated with dementia, including Alzheimer's disease; sleep maintenance insomnia; major depressive disorders; and autism spectrum disorders, PTSD, and IED. The company also develops ITI-002 phosphodiesterase (PDE) 1 inhibitors, including ITI-214 program that is in Phase-I clinical trial for the treatment of cognitive dysfunction in schizophrenia, as well as in pre-clinical stage for the treatment of Parkinson's disease, cognitive impairment in Alzheimer's disease, and attention deficit/hyperactivity disorders; and ITI-002 internal program that is pre-clinical stage for cardiovascular and other diseases. In addition, it develops early stage drug development programs comprising ITI-012 casein kinase 1 inhibitors and ITI-009 gamma secretase activating protein inhibitors for Alzheimer's disease. Further, the company develops PDE2 and PDE9 targets for treating neurodegeneration and bioenergetic failure in various CNS diseases. It has a license and collaboration agreement with Takeda Pharmaceutical Company Limited to research, develop, and commercialize the company's proprietary compound ITI-214 and other selected compounds that selectively inhibit PDE1 for use in the prevention and treatment of human diseases. The company is headquartered in New York, New York.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Neuroscience Drug Development Disorders Mental Health Alzheimer's Disease Dysfunction Schizophrenia Parkinson's Disease Psychiatric Diagnosis Psychiatry Dementia Major Depressive Disorder Depressive Disorder Takeda Pharmaceutical Company Human Disease Neurodegeneration Treatment Of Parkinson's Disease Aging Associated Diseases Attention Deficit Human Diseases Hyperactivity Disorder Cognitive Disorders Bipolar Disorder Insomnia Psychiatric Disorders Autism Spectrum Disorder Cognitive Impairment Cognitive Dysfunction Learning Disabilities Major Depressive Disorders Phosphodiesterase Autism Bipolar Disorders Cardiovascular And Other Diseases Pde9

Is ITCI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 40.0
52 Week Low 17.26
Average Volume 463,358
200-Day Moving Average 29.12
50-Day Moving Average 33.52
20-Day Moving Average 33.75
10-Day Moving Average 35.36
Average True Range 1.78
ADX 20.22
+DI 27.45
-DI 15.14
Chandelier Exit (Long, 3 ATRs ) 33.42
Chandelier Exit (Short, 3 ATRs ) 34.13
Upper Bollinger Band 38.91
Lower Bollinger Band 28.58
Percent B (%b) 0.87
BandWidth 30.59
MACD Line 1.23
MACD Signal Line 0.66
MACD Histogram 0.5735
Fundamentals Value
Market Cap 3.01 Billion
Num Shares 80.2 Million
EPS -2.81
Price-to-Earnings (P/E) Ratio -13.36
Price-to-Sales 147.02
Price-to-Book 2.70
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.16
Resistance 3 (R3) 40.21 39.40 39.73
Resistance 2 (R2) 39.40 38.75 39.38 39.59
Resistance 1 (R1) 38.50 38.35 38.10 38.45 39.45
Pivot Point 37.70 37.70 37.50 37.67 37.70
Support 1 (S1) 36.80 37.05 36.40 36.75 35.75
Support 2 (S2) 35.99 36.64 35.97 35.61
Support 3 (S3) 35.09 35.99 35.47
Support 4 (S4) 35.04